A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults

NCT05827926 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 1758

Last updated 2025-12-23

Study results available
· View outcomes & findings →

Summary

The study is divided into 2 parts: Part 1 and Part 2. The purpose of Part 1 of this study is to generate sufficient safety, reactogenicity, and immunogenicity data to enable selection of an mRNA-1083 vaccine composition and dose level to evaluate in a subsequent Phase 3 clinical trial in adults.

The purpose of Part 2 of this study is to generate safety and immunogenicity data for additional mRNA-1083 compositions and dose levels in young adults ≥18 years and \<50 years of age.

Conditions

Interventions

BIOLOGICAL

Influenza Vaccine 1

quadrivalent seasonal influenza vaccine

BIOLOGICAL

mRNA-1083.1

Sterile liquid for injection

BIOLOGICAL

mRNA-1083.2

Sterile liquid for injection

BIOLOGICAL

mRNA-1083.3

Sterile liquid for injection

BIOLOGICAL

Investigational Influenza Vaccine 1

Sterile liquid for injection

BIOLOGICAL

Investigational COVID-19 Vaccine 1

Sterile liquid for injection

BIOLOGICAL

COVID-19 Vaccine 1

Sterile liquid for injection

BIOLOGICAL

Investigational Influenza Vaccine 2

Sterile liquid for injection

BIOLOGICAL

Influenza Vaccine 2

quadrivalent seasonal influenza vaccine

BIOLOGICAL

mRNA-1083

Sterile liquid for injection

BIOLOGICAL

Investigational COVID-19 Vaccine 2

Sterile liquid for injection

BIOLOGICAL

COVID-19 Vaccine 2

Sterile liquid for injection

Sponsors & Collaborators

  • ModernaTX, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-04-14
Primary Completion
2024-12-03
Completion
2024-12-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05827926 on ClinicalTrials.gov